Clinical and economic evaluation of tralokinumab for atopic dermatitis.

IF 2.3 4区医学 Q2 HEALTH CARE SCIENCES & SERVICES

Journal of managed care & specialty pharmacy Pub Date : 2024-07-01 DOI:10.18553/jmcp.2024.30.7.639

Ryan A Moreau, Angela Y Su, Molly M Csere, Ryan M Shan, Christina M Polomoff

引用次数: 0

Abstract

Tralokinumab is the first selective interleukin 13 inhibitor approved for moderate to severe atopic dermatitis. This article reports the findings of a comprehensive literature review and extensive economic analysis to assess tralokinumab's safety, effectiveness, and cost. Evidence synthesis involved evaluating comparative effectiveness and conducting economic sensitivity analyses. This review was prepared by the University of Connecticut School of Pharmacy Academy of Managed Care Pharmacy (AMCP) Student Chapter. The student author group won the AMCP National Pharmacy and Therapeutics competition for their tralokinumab product review in March 2023.

查看原文本刊更多论文

曲妥珠单抗治疗特应性皮炎的临床和经济评估。

曲洛单抗是首个获准用于治疗中重度特应性皮炎的选择性白细胞介素 13 抑制剂。本文报告了全面的文献综述和广泛的经济分析结果，以评估曲妥珠单抗的安全性、有效性和成本。证据综合包括评估比较有效性和进行经济敏感性分析。本综述由康涅狄格大学药学院管理护理药学学会 (AMCP) 学生分会撰写。学生作者小组的曲妥珠单抗产品综述于 2023 年 3 月赢得了 AMCP 全国药学和治疗学竞赛。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of managed care & specialty pharmacy Health Professions-Pharmacy

CiteScore

3.50

自引率

4.80%

发文量

131

期刊介绍： JMCP welcomes research studies conducted outside of the United States that are relevant to our readership. Our audience is primarily concerned with designing policies of formulary coverage, health benefit design, and pharmaceutical programs that are based on evidence from large populations of people. Studies of pharmacist interventions conducted outside the United States that have already been extensively studied within the United States and studies of small sample sizes in non-managed care environments outside of the United States (e.g., hospitals or community pharmacies) are generally of low interest to our readership. However, studies of health outcomes and costs assessed in large populations that provide evidence for formulary coverage, health benefit design, and pharmaceutical programs are of high interest to JMCP’s readership.